These steroids come in various strengths, with lower-potency options available over the counter and higher-potency creams as a prescription. But they're not meant to be a long-term solution for the ...

Medical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis. 3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in ...

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

Sleep loss from itching is one of the hardest parts of caring for a child with eczema. Here’s a guide to relieving night flares — and helping the whole family rest easier.

Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...

Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or its treatments may contribute to ocular surface disease. In this Q&A ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...